Sugi Predict

Sugi Predict / Compounds / SCHEMBL159651

SCHEMBL159651

SCHEMBL159651

NC(=O)c1ccc(Br)cc1N

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.62
▸ KDM4E B2RXH2 1/20 0.53
▸ GLA P06280 1/20 0.53
▸ PLAU P00749 1/20 0.50
▸ MAPT P10636 5/20 0.47
▸ POLB P06746 1/20 0.47
▸ PARP1 P09874 1/20 0.45
▸ CASP1 P29466 2/20 0.42
▸ CES2 O00748 1/20 0.42
▸ GALR3 O60755 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.41
▸ IKBKB O14920 1/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147774 0.83 KDM4E (0.70) DGAT1KDM4EGLAPLAUMAPT
SCHEMBL148392 0.83 KDM4E (0.70) DGAT1KDM4EGLAPLAUMAPT
SCHEMBL2344362 0.82 DGAT1 (0.67) DGAT1KDM4EGLAPLAUMAPT
Hydrochloric Acid SCHEMBL6359504 0.81 KDM4E (0.68) DGAT1KDM4EGLAPLAUMAPT
SCHEMBL13967325 0.81 KDM4E (0.52) DGAT1KDM4EGLAPLAUMAPT
SCHEMBL1189192 0.81 KDM4E (0.52) DGAT1KDM4EGLAPLAUMAPT
SCHEMBL20808925 0.80 DGAT1 (0.64) DGAT1KDM4EGLAPLAUMAPT
Hydrochloric Acid SCHEMBL856910 0.79 KDM4E (0.50) DGAT1KDM4EGLAPLAUMAPT
Nitrogen SCHEMBL28650271 0.79 KDM4E (0.66) DGAT1KDM4EGLAPLAUMAPT
Methyl Alcohol SCHEMBL29017641 0.79 KDM4E (0.66) DGAT1KDM4EGLAPLAUMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569925-A1 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2005-09-07 — — EP claimed
WO-2004055003-A1 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-07-01 — — WO claimed
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
EP-4698544-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2026-02-25 — — EP disclosed
EP-4608807-A1 PROTEIN DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-03 — — EP disclosed
WO-2025090412-A1 DCAF1 LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-05-01 — — WO disclosed
WO-2024220946-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2024-10-24 — — WO disclosed
CN-115677616-B Macrocyclic sulfonamide compound, preparation method and medical application thereof 中国药科大学 2024-10-18 — — CN disclosed
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-06-20 — — US disclosed
WO-2024092009-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-05-02 — — WO disclosed
EP-1471910-A2 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS NEUROGEN CORPORATION (US) 2004-11-03 — — EP disclosed
US-20040156869-A1 2-substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION 2004-08-12 — — US disclosed
US-20040142958-A1 Combination therapy for the treatment of pain NEUROGEN CORPORATION 2004-07-22 — — US disclosed
WO-2004054582-A1 COMBINATION THERAPY FOR THE TREATMENT OF PAIN NEUROGEN CORPORATION (US) 2004-07-01 — — WO disclosed
US-20040116422-A1 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2004-06-17 — — US disclosed
US-20040106616-A1 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION 2004-06-03 — — US disclosed
CN-1492860-A Quinazoline derivatives ������ҩ��ʽ���� 2004-04-28 — — CN disclosed
EP-1369418-A1 QUINAZOLINE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2003-12-10 — — EP disclosed
WO-2003062209-A2 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN NEUROGEN CORPORATION (US) 2003-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK1, KLK5 DGAT1 2396/4885KDM4E 794/4885GLA 618/4885
US-20040142958-A1 Combination therapy for the treatment of pain OPRK1, OPRL1, OPRM1 DGAT1 2894/4885KDM4E 4717/4885GLA 4155/4885
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use GIPR, MC2R, GRPR DGAT1 2075/4885KDM4E 3829/4885GLA 2534/4885
US-20040156869-A1 2-substituted quinazolin-4-ylamine analogues PIGS, HRH4, GPR88 DGAT1 4580/4885KDM4E 2859/4885GLA 2128/4885
US-20040106616-A1 Substituted quinazolin-4-ylamine analogues PIGS, HRH4, GPR88 DGAT1 4604/4885KDM4E 3001/4885GLA 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.